Pfizer and Valneva may have about two more years to wait before they make the first approval filing to the FDA for a Lyme disease vaccine, but that hasn’t stopped the companies collecting more positive data in the meantime.
A study from Abbott found that employing its cardiac valve repair implant during earlier phases of heart failure—when a patient’s leaky mitral valve is still considered to be functional—could lead to fewer related hospitalizations while improving health status and quality of life.
The FDA has approved a new type of stent designed specifically for infants and young children—including neonates born with congenital heart defects—that’s designed to expand in size as the child grows.
Arrowhead Pharmaceuticals has shown its hand ahead of a potential showdown with Ionis, publishing phase 3 data on a rare metabolic disease treatment that is racing toward regulators.
Sanofi is still set on taking its multiple sclerosis (MS) med tolebrutinib to the FDA, executives have told Fierce Biotech, despite the BTK inhibitor falling short in two of three phase 3 trials that read out Monday.
Bayer suspended the phase 3 trial for its factor XIa inhibitor asundexian late last year after the drug showed “inferior efficacy” at preventing strokes in patients with atrial fibrillation compared to Bristol Myers Squibb and Pfizer’s Eliquis. The full picture of what that “inferior efficacy” looks like has now come into focus: Patients receiving asundexian actually suffered strokes or systemic embolisms at a higher rate than those receiving Eliquis.
Many microbes are extremophiles, capable of surviving conditions that would spell instant death for you and me. From deep-sea hydrothermal vents to boiling hot springs, these single-celled creatures have evolved special tools to help them thrive in tough places. Researchers have long wanted to harness these tools for human applications.
U.S. stocks edged back from their records as Wall Street counted down to a big jobs report that’s coming on Friday
U.S. donors gave $3.6 billion on Tuesday, an increase from the past two years, according to estimates from the nonprofit GivingTuesday
Lawmakers from states with legalized gambling are proposing standards for other states that are considering allowing internet betting
Edgewise’s stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos
In 2 papers, researchers describe potential new neurodegenerative disease treatment approach
Aligos’ MASH prospect slashes liver fat in phase 2, but stock drops anyway
Vanda receives FDA rejection, issues fiery response against ‘conclusory’ refusal
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
Achilles drops cell therapy program, braces for layoffs after missing ‘commercial viability’ goals
Basilea scores $268M BARDA funding deal to work on antifungals, antibiotics
From ‘science fiction to reality’: New George Church-founded biotech raises $75M for cell therapy platform
How the Stock Market Defied Expectations Again This Year, by the Numbers
US Applications for Unemployment Benefits Hold Steady, but Continuing Claims Rise to 3-Year High
